Highlights from Day 3 of ASH 2024

The 66th ASH Annual Meeting and Exposition held from December 7-10, 2024, in San Diego, California.

It brought together over 30,000 health professionals, clinicians, researchers, educators, and industry leaders from around the world. As the most comprehensive hematology event of the year, the meeting offered a unique opportunity for attendees to engage with the latest advancements in blood-related disorders, treatment innovations, and groundbreaking research.

The conference featured a wide range of sessions, including scientific presentations, educational symposia, and hands-on workshops, designed to foster collaboration and knowledge exchange across various sectors of hematology. Participants had access to cutting-edge research findings, emerging therapies, and best practices in patient care, making it a vital event for professionals looking to stay at the forefront of the field.

Doctors and healthcare professionals shared their highlights on social media:

Naveen Pemmaraju:

“Epic all-world MPN group ASH Selfie after final MPN oral session!! Most wonderful group of dedicated researchers!”

Mohamad Mohty:

“This is likely the breaking news of the day at ASH24
Aquila soars high,
Hope in smoldering shadows,
New light breaks the dark.”

Joshua Zeidner:

“Very interesting study and exceptional presentation by Daniel Pollyea on Aza/Ven frontline Tx in younger adults at ASH24. Intensive chemo for all younger fit AML may need to be redefined. Kudos to Daniel Pollyea et al for conducting this important study.”

Talha Badar:

“Phase 1 study of oral AZA+cedazuridine in MDS, MDS/MPN presented by Dr. Garcia Manero

AE’s and efficacy comparable to IV AZA.”

AI-Ola A Abdallah:

“The DREAMM-7 trial clearly demonstrated a PFS advantage for BVd over DVd, and now we are witnessing an OS improvement! will Belantamab return? And which LOT this combination will be used?

Full disclosure I am a co-author for the DREAMM-7 study.”

Ruben A. Mesa:

“Amazing ASH24 for team at Atrium Health Levine Cancer and Wake Cancer over 130 abstracts, invited presentations and the start of our own Belinda Avalos as ASH President!! ASH kudos to amazing job running meeting by ASH staff!”

Chadi Nabhan:

“Ahead of SMM RCT oral (now NEJM paper). I caught up with Vincent Rajkumar of Mayo Clinic who shared the data annd its implications on clinical practice for Healthcare Unfiltered audience annd others.
Kudos to all investigators on this critical milestone. Must watch.”

Rahul Banerjee:

“ASH24 and the best for last! Our fearless US MM consortium leader Doris Hansen presenting the most sophisticated analysis of cilta-cel vs ide-cel in RW practice I’ve ever seen!

Yes, an RCT will be ideal – but will never happen this decade. So what do our current data show.”

Tammarah Sklarz:

“Incredibly proud to be on this wall with these inspiring people. The future of hematology is strong, diverse, beautiful and hopeful. The ASH Career Development Awards foster growth and amazing connections. Honored to be a part of this network.”

Keisuke Ito:

“Had a delightful dinner with my clinical mentor, Dr. Masahiro Kizaki, at ASH24 in San Diego! So grateful for his amazing support over past 25 years. He invited me to speak at JSH2017 as its president. Can’t wait to be a speaker at JSH2025 in Kobe, Japan!”

Inci Aydemir:

“Thank you to all the scientists from around the world who showed interest in my work, shared insightful questions, and provided valuable feedback! Wrapping up my first ASH24 meeting with wonderful memories, see you next year in Orlando, folks!”

Vincent Rajkumar:

“For ASH24. Active myeloma drugs in one table with mechanism of action. Bookmark!

Black font — Approved drugs
Blue font — Investigational.”

Paul De Santis:

“Putting CAR T to shame in r/r DLBCL. These guys make it look easy Martin Hutchings, Michael Dickinson among many others….

1 Englumafusp Alfa (CD19-4-1BBL + Glofit (77% CR in 2L aNHL 👀),

2 Glofit + Pola (66% CR in HGBCL)

3 Mosun + Pola (58% CR, 0% Gr3+ CRS)…

4 Glofit monotx 56% of patients with a CR at any time remained in remission at 24 months…should be noted other CD20 BsAbs showed similarly strong data as well.”

Irene Ghobrial:

“Immune profiling. Amazing data by the master! Thanks to Bruno we have immune markers to predict CART outcome.”

David J Young:

“Dr. Rachael Grace of DFBC Pediatric Care presents a comprehensive analysis of pedi AIHA. Half of patients will have one episode. For the it is a recurrent condition. With 70% untested, there is a need for more universal genetics to help stratify risks/treatment.

At an ASH24 that saw the wonderful blinatumomab results, it is frightening that pediatric AIHA can have mortality rates approaching 10%. We need better diagnostics, understanding and treatments.”

Nikhil Vojjala:

“Grateful to meet my mentor in person! Thank you for all the opportunities and mentorship!”

Ahmed Kotb:

“Late infection prophylaxis post-CAR T:

Bacterial: Levofloxacin – Until recovery

Fungal: Fluconazole or Posa – Until recovery

Herpes: Acyclovir – 6M/CD4>200

PJP: TMP-SMX – 6M/CD4>200.”

Laura Korin:

“One of the highlights of the ASH24 mid career networking session. I can’t help myself and I need this picture taken ASAP.”

Bertrand Delsuc:

“Evaluation of $AZN AZD0486, a novel CD19xCD3 TCE in R-R DLBCL in an ongoing FIH phase 1-High CRs seen in CAR-T-naive and CAR-T-exposed patients.

only n=5 CAR-T-naive at 7.2mg makes it hard to understand if the dose response is the pot. bell shape curve expected with bispecs

Evaluation of $AZN AZD0486, a novel CD19xCD3 TCE in R-R DLBCL in an ongoing FIH phase 1-High CRs seen in CAR-T-naive and CAR-T-exposed patients, only low Gr (1/2) CRS, still some Gr3 ICANS

looking good overall.”

Beth Faiman:

“BCL2 inhibitors in myeloma and Amyloidosis? Yes please! Lisaftoclax in RRMM.”

Richa Thakur:

“Shoutout to Dima Danai for a fabulous presentation on teclistimab in pts receiving prior BCMA directed therapies. Yes, tec is still a viable option. But pretreated patients (especially if less than 9 mo) may possibly have worse PFS and OS.”

Naveen Pemmaraju:

“A new era starts
Now Targeting mutations
JAK, CALR – beware!”

Highlights from ASH24 Day 1

Highlights from ASH24 Day 2